Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles
Viatris Inc. navigates a competitive landscape with improved financial performance, driven by new product launches like Breyna and Wixela. The company aims for a 3.0x leverage ratio by 2024, with analysts projecting FY2024 EPS at $2.72 and FY2025 at $2.57. Debt reduction and strategic divestitures enhance financial flexibility, but pricing pressures and competitive challenges persist.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
Teva Pharmaceutical Industries Limited's TEVA stock declined 10% despite strong Q3 results, driven by underwhelming guidance. The company's branded drugs Austedo and Ajovy are key growth drivers, with expected sales of $1.6 billion and $500 million in 2024, respectively. Teva's generics and biosimilars pipeline is robust, with several launches expected by 2027. The company resolved opioid litigation for $4.25 billion, and its stock valuation is attractive, making it a potential buying opportunity for long-term investors.
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers
Regeneron and Sanofi's Dupixent gains FDA approval for COPD, becoming the first targeted therapy for the condition, with a Phase 3 trial showing reduced exacerbations and improved lung function.
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
AstraZeneca, Daiichi revise approval plans for Enhertu successor
AstraZeneca and Daiichi Sankyo withdrew an approval application for lung cancer drug dato-dxd, replacing it with a new one targeting EGFR-mutated tumors, aiming for an 'accelerated' approval in previously treated patients. This decision, based on pooled analysis showing pronounced benefit in EGFR-mutated patients, could limit the drug's sales potential.
Viatris to Report Q3 Earnings: What's in the Cards?
Viatris (VTRS) to report Q3 results on Nov. 7, 2024; Zacks Consensus Estimate for revenues at $3.68B and earnings at $0.68/share. Developed Markets expected to contribute $2.2B, Emerging Markets $567M, JANZ $396M, and Greater China $562M. Brand business growth in Emerging Markets, JANZ, and Greater China offset by unfavorable dynamics in North America and price regulations in Japan/Australia. Generics business improved due to new product launches and strong performance in Europe. Operating expenses likely increased due to SG&A investments and R&D progress.
Goa unit clearance brings cheer for Cipla, lifts earnings visibility
Cipla's Goa manufacturing facility, cleared after regulatory hurdles, paves the way for the launch of key oncology drug Abraxane, expected to be a $120 million opportunity. Brokerages upgrade Cipla's outlook, anticipating significant revenue contributions from the Goa unit and future drug launches, driving stock gains.
AZ, Avillion's Airsupra aces asthma rescue therapy trial
AstraZeneca and Avillion's Airsupra outperformed standard therapy in a phase 3b trial, leading to its early halt. Airsupra, combining albuterol and budesonide, significantly reduced severe asthma exacerbations. Approved in the US since 2023, it targets adults and shows promise in mild to moderate asthma patients, potentially contributing to AZ's respiratory revenues.
SWOT analysis: generic drug maker's stock faces challenges amid growth
Viatris Inc., formed by Mylan and Upjohn, navigates pharma challenges with 5% stock rise vs. S&P 500's 2%. Market cap $14.44B, EPS forecasts $2.66/$2.70. NA GX segment growth driven by Breyna, NPL guidance raised to $500-600M. OTC divestiture by mid-2024 aims for leverage target of 3x. Analysts cautious, Barclays 'Underweight'. Medium-term pipeline promising, FDA GA Depot meeting crucial.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath